Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Stroke Clinical Trial

— NEUROGAIT  

Official title:

Neuromechanical Characterization of Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06107556
• Other study ID #: 2023-A02258-37
• Status: Not yet recruiting
• Start date: October 19, 2023
• Est. completion date: June 30, 2024

Study information

• Verified date: October 2023
• Source: Henri Mondor University Hospital
• Contact: Emilie Hutin, Ph.D.
• Phone: 0149812549
• Email: emilie.hutin[@]aphp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The retrospective study investigates the part of responsibility of neuromuscular disorders associated with chronic hemiparesis in walking impairment.

Description:

After injury to the central nervous system, walking disorders are associated with complex neuromuscular mechanisms that alter the direction and intensity of the descending control, reflex reactions to kinematic changes and the mechanical components of soft tissues. The dissociated analysis of these mechanisms and their interactions during multi-segmental movements and especially during walking is poorly described. However, a quantified assessment of the responsibility of each of the neuromuscular mechanisms in the functional disorder would guide the choice of treatments. 3D gait laboratories provide kinematic data from synchronized walking to surface electromyograms as part of additional assessments to assist in the follow-up of patients with chronic hemiparesis. Retrospective analysis of these data would help to better characterize muscular activation disorders and passive resistance to movement during walking in this population.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: June 30, 2024
• Est. primary completion date: October 19, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult
• Person who performed tridimensional gait analysis in laboratory
• Person who had a stroke at least 6 months before the gait analysis

Exclusion Criteria:

• Any other neurological pathology or gait disorders
• Botulinum toxin injection in the last 3 months before the gait analysis

Related Conditions & MeSH terms

• Mobility Limitation
• Paresis
• Stroke
• Trauma, Nervous System
• Walking, Difficulty

Intervention

Diagnostic Test:
• Gait analysis
3D gait analysis with electromyographic measurements

Locations

Country	Name	City	State
France	Laboratoire Analyse et Restauration du Mouvement	Créteil

Sponsors (1)

Lead Sponsor	Collaborator
Henri Mondor University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Coefficient of antagonist activation	The coefficient of antagonist activation of gastrocnemius medialis and soleus was calculated from EMG data by the ratio between the root mean square amplitude during antagonist effort and maximal agonist effort for the same muscle.	1 year